Task force 3: Disclosure of relationships with commercial interests: policy for educational activities and publications.

نویسندگان

  • Alice K Jacobs
  • Bruce D Lindsay
  • Bruce J Bellande
  • Gregg C Fonarow
  • Rick A Nishimura
  • Pravin M Shah
  • Brian H Annex
  • Valentin Fuster
  • Raymond J Gibbons
  • Marcia J Jackson
  • Shahbudin H Rahimtoola
چکیده

tween industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 2004; 170:477– 80. 22. Relman AS, Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. New Repub 2002; 227:27– 41. 23. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA 2003;290:495–501. 24. Dickersin K, Rennie D. Registering clinical trials. JAMA 2003;290: 516–23. 25. Hrachovec JB, Mora M. Reporting of 6-month vs. 12-month data in a clinical trial of celecoxib. JAMA 2001;286:2398–400. 26. McKillop T. The statin wars. Lancet 2003;362:1498. 27. Nathan DG, Weatherall DJ. Academia and industry: lessons from the unfortunate events in Toronto. Lancet 1999;353:771–2. 28. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. Available at: www.icmje.org/ index.html#conflicts. 29. P.L. 96-517; 94 Stat. 3015 The Bayh-Dole Act. 12-12-1980. 30. Stolberg SG. The biotech death of Jesse Gelsinger. NY Times Magazine 1999;136–50. 31. Califf RM, Morse MA, Wittes J, et al. Toward protecting the safety of participants in clinical trials. Control Clin Trials 2003; 24:256 –71.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Dementia Screening Tools for the Primary Care Physician

Release Date: February 1, 2007 Expiration Date: April 30, 2007 Estimated Time to Complete: 1 hour FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any oth...

متن کامل

ASN policy on managing conflicts of interest.

The federal government, foundations, associations, and the Institute of Medicine (IOM) are examining the relationships between physicians and “commercial interests,” particularly biotechnology, medical device, and pharmaceutical companies (Table 1). Discovering a lack of “systematic information” about conflicts of interest (COI) and commercial bias, IOM recently recommended that the federal gov...

متن کامل

Significant Financial Interest (non-PHS) Consistent with the University of California?s definition (See University of California Policy On Disclosure of Financial Interests and Management of Conflicts of Interest Related to Sponsored Projects) Significant Financial Interest means anything of monetary value

This policy describes the conditions under which these financial interests should be disclosed by all Investigators. The procedure is applicable to all research and educational activities supported by sponsors and programs, including the National Science Foundation, who continue to follow the 1995 regulations on Objectivity in Research [See 60 F.R. 35810 [2] (July 11, 1995), 42 C.F.R. Part 50, ...

متن کامل

Melanoma, Version 2.2013

The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the clinical management of patients with melanoma. This NCCN Guidelines Insights report highlights notable recent updates. Foremost of these is the exciting addition of the novel agents ipilimumab and vemurafenib for treatment of advanced melanoma. The NCCN panel also included imatinib as a treatment for KIT-mutated t...

متن کامل

Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries

Relationships between health professionals and pharmaceutical manufacturers can unduly influence clinical practice. These relationships are the focus of global transparency efforts, including in Europe. We conducted a descriptive content analysis of the transparency provisions implemented by February 2017 in nine European Union (EU) countries concerning payments to health professionals, with du...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Journal of the American College of Cardiology

دوره 44 8  شماره 

صفحات  -

تاریخ انتشار 2004